Fig. 2.

HER3 is required for expansion of MET-amplified cancer cells in vitro and in vivo. a Western blot analysis of total and phosphorylated levels of HER3 in the indicated cell lines stably transduced with control (pLKO) or shRNAs targeting HER3. Quantification of HER3 relative to tubulin (n = 3). b Live-cell imaging to measure cell confluence of the indicated cell lines stably transduced with control (pLKO) or shRNAs targeting HER3. Representative replicates are shown (n = 3); error bars indicate SD. c–d Representative images of colony-forming assay are presented. c Quantification of colony-forming capacity of KatoII cells in soft agar (colonies > 200 μm) (n = 4). Error bars indicate SEM. d Quantification of colony-forming capacity in H1993 cells (n = 3). Error bars indicate SEM. e–f Tumor growth of the indicated cell lines engraft in the flank of immunocompromised mice (NSG), n = 10. One-way ANOVA with Dunnett’s test for multiple comparisons: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.000